MEDVi QUAD Review 2026: Formula, Price, Safety, and -product page Conflicts

Affiliate disclosure: Some links in this article are affiliate links. If you purchase through them, VitaminsForMen.com may earn a commission at no additional cost to you. This does not influence our research or conclusions. See our How We Review page for full details. MEDVi QUAD is a compounded prescription medication requiring evaluation by a licensed clinician. Compounded medications are not FDA-approved as finished drug products. Prescription approval is not designed to deliver. This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any prescription treatment.

By VFM Research Desk | Last verified: August 2026

Methodology: This review is based on MEDVi’s published root and alternate marketing pages as captured August 6, 2026, MEDVi’s published Terms & Conditions, and publicly accessible regulatory information. No product was independently tested. No payment was received from MEDVi for this review.

Medical review status: This content has not been independently reviewed by a named licensed medical professional. All clinical facts are sourced from FDA prescribing information and publicly available regulatory records as cited. Consult a qualified healthcare provider before making any prescription treatment decision.

MEDVi QUAD Review 2026: Formula, Price, Safety, and Official-Page Conflicts

Quick Answer: As of August 6, 2026, MEDVi’s canonical QUAD root page displayed a compounded sublingual formula containing PT-141 (bremelanotide), L-citrulline, sildenafil, and tadalafil, starting at $114/month. A simultaneously live official /hm-alt route displayed a different top-card formula with apomorphine, vardenafil, sildenafil, and tadalafil at different starting prices. This article reports what each official MEDVi route displayed on that date and does not claim either marketing page establishes the exact formula or final price you will receive. PT-141’s FDA-approved indication is acquired, generalized HSDD in premenopausal women via subcutaneous injection, not sublingual male ED. Apomorphine’s FDA-approved indication is acute off episodes in Parkinson’s disease via subcutaneous injection. Neither approved indication transfers to a compounded sublingual male-ED combination. Verify your exact prescription, route, formula, and checkout total directly with MEDVi before paying.

This review examines what MEDVi’s official marketing pages showed as of August 6, 2026. The two official routes displayed different formulas and prices on the same capture date, creating an internal conflict that readers deserve to understand before enrolling.

What MEDVi QUAD Actually Is

MEDVi QUAD is a compounded prescription medication, so the FDA has not reviewed or approved it as a finished drug product before marketing. MEDVi says its service uses clinician review and partner pharmacies. We did not independently verify the legal name or current state license of the dispensing pharmacy for a reader’s order. Confirm the prescriber, pharmacy, prescription, and pharmacy label before paying.

The practical implication: the compounded combination itself — including its exact formulation, strengths, and sublingual route — is not an FDA-approved drug product. Sildenafil and tadalafil have approved oral products for male ED. PT-141/bremelanotide has an approved injected product for a specific female desire disorder, not male ED. L-citrulline is not an FDA-approved drug. Ingredient-name overlap does not establish clinical equivalence.

MEDVi’s Official-Page Formula and Price Conflict

On August 6, 2026, MEDVi’s official root page and official /hm-alt page displayed conflicting formula and price states. Both described a sublingual liquid; the conflict is the page content, not the dosage route.

MEDVi’s linked root page displayed:

• Formula: PT-141, L-citrulline, sildenafil, tadalafil
• Route: Rapid-absorb sublingual liquid
• Advertised starting price: $114/month

MEDVi’s /hm-alt route top card displayed:

• Formula: Apomorphine, vardenafil, sildenafil, tadalafil
• Route: Rapid-absorb sublingual liquid
• Displayed separate $119 and $179 starting-price blocks

The /hm-alt page’s later sections repeated the root formula and later referenced $114. It therefore did not establish one coherent alternate formula or checkout total. This review uses the owner-supplied root as the dated current offer while preserving the alternate page conflict. Verify the exact prescribed formula, quantity, pharmacy, and final charge.

The Four Active Ingredients — What the Regulatory Record Shows

The approved labels for individual drugs do not establish the safety, effectiveness, dose, or timing of the exact compounded QUAD combination. The FDA explains that compounded drugs are not pre-reviewed for safety, effectiveness, or quality.

Sildenafil has an approved oral product label for erectile dysfunction. That label does not establish MEDVi’s compounded sublingual combination, strength, timing, or effectiveness.

Tadalafil also has an approved oral product label. Ingredient-name overlap does not establish the finished compounded route or combination.

Vardenafil appears in the /hm-alt top card and has an approved oral label with QT-related cautions. The approved oral label does not validate a compounded sublingual product.

PT-141 (bremelanotide) is not a PDE5 inhibitor and is not Levitra. The approved Vyleesi label covers a subcutaneous injection for acquired, generalized HSDD in premenopausal women — not male ED or compounded sublingual delivery.

Apomorphine appears in the /hm-alt top card. The approved APOKYN label covers a subcutaneous injection for Parkinson OFF episodes, not ED or sublingual delivery. Its hypotension, fainting, QT, and 5-HT3-antagonist warnings are prescriber-review questions with a route caveat, not proof of the compounded product’s risk magnitude or efficacy.

L-citrulline is an amino acid and is not an FDA-approved drug. It is not apomorphine, APOKYN, Uprima, a dopamine agonist, or an approved Parkinson’s treatment. The public MEDVi root page lists it, but the checked source did not disclose its exact strength or establish what incremental benefit it adds to the finished combination.

Who This Is For and Who This Is NOT For

If you take a nitrate medication, do not use a PDE5-containing MEDVi formula. Approved PDE5 labels contraindicate nitrates because the combination can cause dangerous blood-pressure reduction. Disclose nitroglycerin, isosorbide products, and recreational nitrites during intake. Related reading: Quad by MEDVi Review: What You Need to Know About This Male Enhancement Formula.

Disclose alpha-blockers and other blood-pressure medicines before a PDE5 prescription. If the proposed formula contains apomorphine, ask how the approved injected APOKYN label’s hypotension and fainting warnings affect the different compounded sublingual route.

Readers who prefer an FDA-approved finished product can ask the prescriber how approved oral sildenafil or tadalafil differs from the proposed compounded combination, including route, strength, evidence, and cost.

Pricing, Auto-Renewal, and Refund Policy

Pricing is listed inconsistently across MEDVi’s official pages. The root advertises $114 per month. /hm-alt displays separate $119 and $179 starting-price blocks and later references $114. Verify the exact charge, quantity, renewal date, and prescribed formula at checkout.

MEDVi’s general financial consent describes auto-renewing programs. Its separate subscription and refund policy states that cancellation requests must arrive at least 72 hours before billing. These are platform-wide policies; confirm that they are incorporated into the QUAD checkout and verify the product-specific quantity, refill cadence, and refund terms before paying.

Approved-Label Boundaries and What Remains Unknown

Approved ingredient labels do not establish this compounded sublingual male-ED product. The approved Vyleesi and APOKYN products have different routes, populations, and indications. L-citrulline is not an FDA-approved drug. Preserve those boundaries instead of treating ingredient names as approval for the finished formula.

For a detailed comparison of what the approved labels actually permit and what remains unknown in compounded sublingual use, see approved-label limits for apomorphine and PT-141.

What remains unverified: the exact prescribed formula for your case, the exact strengths in each ingredient, whether every patient receives one of the two official formulas or whether other compounding variations exist, the exact final charge at checkout, the exact dispensing pharmacy, the exact prescription label you will receive, and the finished-product safety profile of the compounded combination as you will receive it.